Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valacyclovir + mecobalamin is a combination therapy used for the treatment of herpes zoster (shingles). Valacyclovir hydrochloride is an antiviral prodrug that is converted to acyclovir, which inhibits viral DNA polymerase, thereby blocking the replication of the Varicella-Zoster Virus (VZV). Mecobalamin, a coenzyme form of Vitamin B12, is utilized as a neuroprotective agent to promote nerve repair and alleviate neuropathic pain, such as postherpetic neuralgia, which is a common complication of herpes zoster. This specific combination is being evaluated by the First People's Hospital of Hangzhou in clinical studies to investigate its immunomodulatory effects and therapeutic outcomes when administered alongside electroacupuncture in patients with herpes zoster.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valacyclovir + mecobalamin.